370 related articles for article (PubMed ID: 36140182)
1. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.
Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X; Zhang J; Chen S; Wang X; Xi Q; Shen H; Zhang R
Cancer Biol Med; 2024 May; ():. PubMed ID: 38801082
[TBL] [Abstract][Full Text] [Related]
3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
4. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
Wang L; Bai L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
[TBL] [Abstract][Full Text] [Related]
5. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
6. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
[TBL] [Abstract][Full Text] [Related]
7. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB; Ha SJ; Kim HR
Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
[TBL] [Abstract][Full Text] [Related]
8. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.
Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
[TBL] [Abstract][Full Text] [Related]
12. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L; Li Y; Tan J; Xu L; Li Y
J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.
Kamali AN; Bautista JM; Eisenhut M; Hamedifar H
Ther Adv Vaccines Immunother; 2023; 11():25151355231192043. PubMed ID: 37662491
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
15. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Torphy RJ; Schulick RD; Zhu Y
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
[TBL] [Abstract][Full Text] [Related]
16. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
[TBL] [Abstract][Full Text] [Related]
17. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Yeo J; Ko M; Lee DH; Park Y; Jin HS
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
Zheng Q; Xu J; Gu X; Wu F; Deng J; Cai X; Wang G; Li G; Chen Z
Am J Transl Res; 2020; 12(7):3212-3224. PubMed ID: 32774695
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets.
Wang J; Zhao Y; Liao P; Huang S; Huang Y; Chen S; Li Y; Zhong L
Blood Sci; 2024 Jan; 6(1):e00181. PubMed ID: 38226018
[TBL] [Abstract][Full Text] [Related]
20. Emerging Targets of Immunotherapy in Gynecologic Cancer.
Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
